Peripheral blood flow cytometry confirmed a T-PLL with lymphocytes expressing CD2, CD3, CD4, CD5, CD7, CD26, and CD52
CDI has released its latest product, the CD52
"Bandit", which is a permanent installation non-instrusive pig passage indicator that detects and records the times and dates of the last 10 pigs.
Aratana's biologics portfolio also includes, AT-005, a canine lymphoma monoclonal antibody targeting CD52
as an aid in the treatment of T-cell lymphoma in dogs, which received a conditional license from the USDA in January 2014.
Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52
, on cell surfaces and directs the body's immune system to destroy those cells.
Carlos Rodriguez of the University of California at Davis presented a poster on the Company's caninized MAb against CD52
for the treatment of T-cell Lymphoma titled, "Bioavailability and Safety of Caninized Anti-CD52
Monoclonal Antibody in Dogs With T-cell Lymphoma.
molecule is a cell surface glycoprotein of mostly unknown function that is expressed on T-cells and B-cells, NK cells and professional antigen-presenting cells.
Therapeutic treatment with an anti-mouse CD52
antibody reverses disease symptoms in a murine EAE model of multiple sclerosis (Poster Session 2 - P908; October 12; 3:30 p.
These include monoclonal antibodies against CD52
(alemtuzumab, Campath[R]), CD20 (rituximab, Rituxan[R]) and CD25 (daclizumab, Zenapax[R]) antigens.
By selectively targeting the CD52
antigen, expressed at higher concentration on malignant lymphocytes, MabCampath activates cellular processes that lead to the lysis of malignant cell types.
NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that the United States Department of Agriculture (USDA) has granted conditional approval for AT-005, Aratana's canine-specific monoclonal antibody against CD52
, which is intended as an aid in the treatment of T-cell lymphoma in dogs.
MabCampath/Campath has a completely different mode of action compared with conventional therapy by selectively targeting the CD52
antigen on the malignant lymphocytes.
The patent also has claims directed to both canine CD20 & CD52
and a divisional directed to methods of treatment.